Fig. 12

A male patient 45 years old diagnosed to have NSCLC received chemotherapy. Baseline study (A and B) showed the mass lesion = 35.3 × 34.4 mm on average with SUV uptake = 2.9. On follow-up after 3 months (Af and Bf) showed decrease in the size of the mass by CT = 29.6 × 29.5 mm in average interpreted as stable disease by RECIST criteria (the decrease in size not met the criteria of partial response by RECIST criteria) while in PET/CT, the SUV increased to be 6.04 instead of 2.9 leading to change in opinion to be progressive disease response by PERCIST criteria instead of stable disease by RECIST criteria